Senjun Liu1, Shuping Liu1, Yebo Zhong1, Qi You2
1Department of Hematology, Lishui City People’s Hospital, Lishui, Zhejiang Province 323000; 2Department of Clinical Lab, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China.For correspondence:- Qi You Email: youqi0216@163.com
Accepted: 28 November 2022 Published: 29 December 2022
Citation: Liu S, Liu S, Zhong Y, You Q. Upregulation of AKAP12 by demethylation inhibits proliferation and increases chemosensitivity to adriamycin in leukemic cells. Trop J Pharm Res 2022; 21(12):2541-2548 doi: 10.4314/tjpr.v21i12.6
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Abstract Purpose: To elucidate the role of AKAP12 in leukemia cells. Methods: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB) were employed to determine the ex Results: The results showed that AKAP12 was lowly expressed in lymphocytic leukemia cell lines (p < 0.001), but was reversed by 5-azacytidine. Transfection of AKAP12 or 5-azacytidine treatment increased the ex Conclusion: AKAP12 is lowly expressed in leukemia cells, and may also play a role in inhibiting leukemia progression by suppressing the activity of PI3K/AKT pathway.Thus, targeting AKAP12 mght be a potential strategy in the management of lukemia.
Archives
News Updates